News

Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit

Noramco Announces the Acquisition of the Cambrex Drug Product Business Unit WILMINGTON, Del. – November 02, 2023 – Noramco, a leading global active pharmaceutical ingredients (API) manufacturer, specializing in controlled substances, announced today it has completed the acquisition of the Cambrex ...
Read More

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide

Noramco Announces Submission and Reactivation of the Drug Master File for Active Pharmaceutical Ingredient Methylnaltrexone Bromide Leverages Company’s Extensive Experience in the Complex Synthesis of Naltrexone-related Products Vertically Integrated Approach Ensures Exceptional Supply Chain Security Wilmington, DE – November 01, ...
Read More

Noramco Celebrates Diversity and International Women’s Day

A Letter to the SK Capital Portfolio Community on International Women’s Day 2022 Dear Respected Colleagues: International Women’s Day (IWD), celebrated on this March 8th, is a global day recognizing the social, economic, cultural, and political contributions and achievements of ...
Read More

Noramco Announces Submission of Drug Master File for Lisdexamfetamine Dimesylate ─ Active Pharmaceutical Ingredient

Leading Producer of Controlled Substance APIs Now Supplying Lisdex API to Generic Drug Manufacturers Preparing for the 2023 Patent Expiry of Top-Selling Branded ADHD Therapy Wilmington, DE – December 3, 2021 – Noramco, LLC, a leading North American producer of ...
Read More

Meet us at DCAT Week

Meet us at DCAT Week March 21 - 24, 2022. The premier business development event for companies engaged in pharmaceutical development and manufacturing. Contact us today to schedule a meeting! Noramco is a global leader in controlled substance APIs for ...
Read More

Noramco Cannabinoids Business to Become Purisys

Two Organizations Will Build on Strengths to Address Differentiated End-Use Markets Wilmington, DE 19 September 2019 – Noramco announced today that its industry-leading cannabinoids business will become a separate company – Purisys, LLC. Purisys will focus exclusively on acting as ...
Read More

Noramco at iCDP

Noramco is a proud partner of the International Cannabinoid Derived Pharmaceuticals Summit (iCDP), taking place on September 10-12, 2019 in Boston, MA. Joshua Hoerner will be presenting on Wednesday, September 11, 2019, at 11:45 am. The topic will be on ...
Read More

Say Hello to Amber Burch

Amber Burch came to Noramco from a small company environment and thoroughly enjoys working at Noramco, “a very dynamic place to work with a lot of growth”. Working at Noramco and understanding the ins and outs of pharmaceutical manufacturing has ...
Read More

Say Hello to Gregory Moore

Gregory Moore joined Noramco as a temp one month after retiring from the U.S. Air Force in August 2014. Within a year, he was hired to a permanent position. Coming to Noramco with no chemical operations experience, Gregory recalls that ...
Read More

Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol

Support for emerging market includes positions on rigorous science, consumer safety and monitoring of intermediates and end-products Wilmington, DE – Noramco, a leading manufacturer of cannabidiol (CBD) and related compounds presented testimony and answered questions at the Food and Drug ...
Read More

Events

DCAT 2023
March 20 – 23, 2023
New York, NY